Reuters logo
1 个月前
BRIEF-Xencor reports interim positive data from ongoing mid-stage study of XMAB5871
2017年6月16日 / 中午12点18分 / 1 个月前

BRIEF-Xencor reports interim positive data from ongoing mid-stage study of XMAB5871

1 分钟阅读

June 16 (Reuters) - Xencor Inc-

* Xencor presents interim data from an ongoing, open-label, phase 2 study of xmab®5871 in igg4-related disease at eular 2017

* Xencor Inc - ‍every other week intravenous administration of xmab5871 in patients with active igg4-rd has been well tolerated​

* Xencor Inc - ‍6 patients attained disease remission (an igg4-rd responder index of 0) in study​

* Xencor Inc - ‍no severe aes deemed related to xmab5871 were reported​

* Xencor Inc - ‍as of april 18, 10 patients have completed study, 3 of whom discontinued early as reported previously in nov 2016, 5 patients are ongoing​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below